Sterne Agee Initiates Coverage on Itron (ITRI) with a Neutral
More News related to ITRI
- Itron to Present at Thomas Weisel Alternative Energy and Natural Resources and Stephens Inc. Fall Investment Conferences
- After-Hours Movers 10/28: GIGA, EGHT, CATM, AKAM, LMAT, LNC Higher; FSLR, FLS, FALC, OI Lower
- Itron (ITRI) Misses Q3 Views
- Itron Announces Third Quarter Results
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
More News related to New Coverage
- Kinross Gold (KGC) Receives Authorization to Re-Commence Exploration on Project in Ecuador
- Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
- Stryker (SYK) Announces Two Acquisitions
- Adobe (ADBE) Cutting 680 Full-Time Jobs to Align Costs with '10 Operating Plan
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
Sterne Agee initiates coverage on Itron (Nasdaq: ITRI) with a Neutral. Price target $56.
To see more analyst ratings on ITRI Click Here.
Itron, Inc. (Itron), provides a portfolio of products and services to utilities for the energy and water markets throughout the world.
Related Categories
New CoverageStocks Mentioned
-0.39Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
